The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.1% (w/w) phenol and above 6.4 mg/ml sodium chloride, their preparation, kits comprising such compositions as well as uses thereof.

The invention provides a method and kits for inhibiting integrin α9β1 activity comprising contacting integrin α9β1 or a binding partner of integrin α9β1 with an isolated anti-integrin α9 inhibitor, wherein the integrin α9β1 activity is inhibited. In certain aspects, the present invention provides a novel intervention by targeting integrin α9β1 with a functional blocking inhibitor (e.g., peptides or antibodies) to limit brain damage following reperfusion after ischemic stroke.

The present disclosure relates to a combination therapy for the treatment of Alport renal disease. In particular, to the treatment of Alport renal disease by administration of both an α1 integrin blocking agent and either an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin-receptor blocker (ARB). Preliminary studies have shown the combination therapy as described herein elongates the onset of end-stage renal disease and other symptoms of Alport renal disease.

The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an α5β1 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).

The present invention relates to a natriuretic peptide selected from the group made up of (i) osteocrin, an osteocrin propeptide of osteocrin derivative, (ii) a lebetin, a lebetin fragment, or a lebetin or lebetin fragment derivative, and (iii) an ANP peptide, ANP propeptide or ANP peptide derivative, for the use thereof in a method for therapeutically treating a bacterial infection associated with a bacterial biofilm in a subject, wherein said natriuretic peptide disperses the bacterial biofilm. In a particular embodiment, the natriuretic peptide is used in combination with an antibiotic.

The two devices described allow for greater control over application of a fibrin biopolymer and yet remain simple enough to be used by both medical personnel and by non-medical workers. One of the devices includes chambers where components necessary for formation of a fibrin biopolymer are stored and are pushed by plungers connected to an actuator upon the actuator receiving pressure from the user, with the components mixing in a chamber within the device and flowing out of a tube connected to the mixing chamber before formation of the fibrin biopolymer is completed. The other device dispenses formulations that include components necessary for formations of a fibrin biopolymer onto a skin of a patient using one or more propellants, with the formation of the fibrin biopolymer being initiated after the formulations are dispensed on the patient's skin and are intentionally mixed together.

The present invention in certain embodiments provides a method of inhibiting PD-1 in a cell by administering a CD200 activation receptor ligand (CD200AR-L) to the cell. The present invention in certain embodiments provides a method of enhancing efficacy of a tumor lysate vaccine in a mammal comprising administering a CD200 activation receptor ligand (CD200AR-L) to the mammal prior to the administration of the tumor lysate vaccine.

The present invention in certain embodiments provides a method of inhibiting PD-1 in a cell by administering a CD200 activation receptor ligand (CD200AR-L) to the cell. The present invention in certain embodiments provides a method of enhancing efficacy of a tumor lysate vaccine in a mammal comprising administering a CD200 activation receptor ligand (CD200AR-L) to the mammal prior to the administration of the tumor lysate vaccine.

A bioactive adhesive for use in securing soft tissue to osseointegrated percutaneous devices includes a hydrogel precursor and a multiplicity of metal-containing mesoporous silicate nanoparticles dispersed throughout the hydrogel precursor. An antimicrobial peptide is adsorbed on surfaces of the mesoporous silicate nanoparticles, incorporated in the mesoporous silicate nanoparticles, or both. The metal-containing mesoporous silicate nanoparticles can include calcium, strontium or both and are configured to release the antimicrobial peptide over time. Adhering tissue to a metal surface includes disposing the bioactive adhesive on a metal surface, contacting a portion of tissue with the adhesive composition, and curing the adhesive composition, thereby adhering the portion of tissue to the metal surface.

The present invention provides the methods and composition useful as a contraceptive by preventing motile sperm from reaching a mature ovum, thereby blocking fertilization and preventing pregnancy. The contraceptive is comprised of halogen functionalized fullerene nanoparticles (halo fullerenes) and chemotactic stimulants that act synergistically to divert, incapacitate and ultimately rupture spermatozoa to avert fertilization. When applied vaginally prior to coitus, the suspension is activated by exposure to spermatozoa upon insemination. Notably, non-spermatozoa cells are unaffected by the pH-neutral suspension; however, closer to the same scale, microbes are susceptible to its inherent biocidal properties. Following application and coitus, the contraceptive evacuates naturally, along with seminal and vaginal fluids thereafter.